Across TCGA pan-cancer cohorts, LRCH3 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated LRCH3 data layer compared with 24 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher LRCH3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated LRCH3 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

HNSC, LUAD, and CCRCC are the cancer types where LRCH3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	III,IV	0.911	0.704	.012	9	view →
LUAD	DFS	Median	II,III,IV	0.709	0.225	.021	7	view →
CCRCC	DFS	Tertile	II,III,IV	1.000	0.361	.016	6	view →
LSCC	DFS	Median	All	0.611	0.869	.044	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: LRCH3 tumor-vs-normal RNA expression · all LRCH3 data types